Flemming Ørnskov, Galderma CEO
August 13, 2024 07:07 AM EDTUpdated 02:01 PM
Pharma
FDA+

Gal­der­ma wins FDA ap­proval for IL-31 drug in chron­ic skin dis­ease

Ayisha Sharma

News Reporter

Gal­der­ma has se­cured FDA ap­proval for a drug it li­censed from Chugai Phar­ma­ceu­ti­cal in 2016 for a chron­ic skin dis­ease known for its itchy bumps …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times